40 critically ill surgical ICU patients show significant reduction in inflammation after 7 days of VSL#3
www.ncbi.nlm.nih.gov
This trial gave 40 critically ill patients in a surgical ICU, a group vulnerable to sepsis, the probiotic VSL#3 for a week and they showed a reduction in inflammatory biomarkers and improvement on a number of indexes.
Enjoying this research? Get deeper insights like this delivered every other week.
Every other week our Premium Members receive deep dives like this alongside Rhonda's commentary and 8+ other hand-picked papers.
FTA:
Evidence suggests that VSL#3 can reduce intestinal permeability by tightening the junctions between the cells in the outer layer of the intestine that in turns reduces the likelihood of translocation of pathogens from the intestine into the blood.
(In other words, by reducing translaction of pathogens, there may be a reduction of systemic inflammation.)